CMC(SH:603122) Sou Hu Cai Jing·2025-08-19 11:17Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, which has a high PE ratio compared to its industry peers [1][2] - HeFu China's closing price on August 19 was 7.25 yuan, reflecting a 2.55% increase, with a rolling PE ratio of 199.97 times and a total market capitalization of 2.886 billion yuan [1] - The average PE ratio for the pharmaceutical commercial industry is 42.14 times, with a median of 30.04 times, positioning HeFu China at 27th among its peers [1][2] Group 2 - As of the first quarter of 2025, two institutions hold shares in HeFu China, with a total of 560,000 shares valued at 0.04 million yuan [1] - HeFu China specializes in international trade and after-sales services related to in vitro diagnostic medical devices and consumables, as well as hospital information management system consulting services [1] - The latest financial results for the first quarter of 2025 show HeFu China achieved revenue of 176 million yuan, a year-on-year decrease of 26.35%, and a net profit of -6,001,192.11 yuan, a year-on-year decline of 184.13%, with a gross profit margin of 16.71% [1]